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Running title: Discrepancies in receptors in OPTIMA prelim 
Abstract: 
Background: There is limited data on results of central re-testing of samples from patients with 
invasive breast cancer categorised in their local hospital laboratories as oestrogen receptor (ER) 
positive and human epidermal growth factor receptor homologue 2 (HER2) negative. 
Methods: The Optimal Personalised Treatment of early breast cancer usIng Multiparameter 
Analysis preliminary study (OPTIMA prelim) was the feasibility phase of a randomised controlled 
trial to validate the use of multiparameter assay directed chemotherapy decisions in the UK 
National Health Service (NHS). Eligibility criteria included ER positivity and HER2 negativity. 
Central re-testing of receptor status was mandatory. 
Results: Of the 431 patients tested centrally, discrepant results between central and local 
laboratory results were identified in only 19 (4.4%; 95% confidence interval 2.5%-6.3%) patients 
(with 21 tumours). On central review, seven patients had cancers that were ER negative (1.6%) 
and/or HER2 positive (13 (3.2%) patients with 15 tumours); including one tumour discrepant for 
both biomarkers. 
Conclusion: Central re-testing of receptor status of invasive breast cancers in the UK NHS setting 
shows a high level of reproducibility in categorising tumours as ER positive and HER2 negative 
and raises questions regarding the costs and the value of central re-testing in this sub-group of 
breast cancers in this setting. 
 
Keywords: Breast cancer; oestrogen receptor; HER2 
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Introduction 
Oestrogen receptor (ER) and human epidermal growth factor receptor homologue 2 (HER2) are 
established biomarkers in invasive breast cancer and form the backbone of clinical decision 
making related to targeted therapies in the adjuvant setting. Although data from external quality 
assurance schemes (such as UK NEQAS ICC), successful participation in which is mandatory for 
UK laboratories, indicates good performance for testing these receptors nationally, there is 
relatively little published evidence comparing local results to central re-testing of local ER and 
HER2 expression in large clinical trial datasets. In particular, information from central laboratory 
testing/validation of series of invasive breast carcinomas that have been designated as ER 
positive and HER2 negative is limited; reports have largely described data from central re-testing 
of breast cancers which have been recorded as HER2 positive in local laboratories, such as in the 
Breast Intergroup Trial N9831 [Roche 2002][Suman 2006]. However, some of these publications 
have indicated alarming proportions of discrepancy in defining HER2 positivity. There are fewer 
publications comparing central repeat testing of hormone receptors from clinical trial samples 
but Viale et al examined 6291 of 8010 tumours from women in BIG1-98 and found that 
central review confirmed 97% of tumours were hormone receptor-positive (defined as ER 
and/or PgR > or = 10%) [Viale 2007]. Using tissue microarrays (TMAS) of tumours from 4,598 
samples from patients in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial, 
219 contained insufficient tumour and 12 were ineligible for other reasons, but of the remainder 
only 42 + 14 were ER negative (1.2%) [Bartlett 2011]. 
 
The accuracy of defining hormone receptor positive and HER2 negative invasive breast cancer 
in local centres is clearly vital for patient management outside of the clinical trial setting, but 
also has significant resource and cost implications within randomised trials where ER and/or 
HER2 are critical components of eligibility. The question remains whether local biomarker 
results are sufficiently robust to allow trialists to avoid the costly re-analysis of biomarkers in 
central laboratories to confirm patient eligibility. To address this question we have examined 
data in the UK setting within OPTIMA prelim.  
 
Material and methods: 
The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis 
preliminary study (OPTIMA prelim) (ISRCTN42400492) was the feasibility phase of a randomised 
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controlled trial designed to validate the use of multiparameter assay directed chemotherapy 
decisions in the UK National Health Service [Bartlett 2013][Stein 2016][Bartlett JM et al. 2016]. 
Patients were aged ≥ 40 years at entry with surgically treated ER positive, HER2 negative primary 
invasive breast cancer, with 1 to 9 involved axillary nodes or, if node negative, a tumour of at 
least 30mm in maximum dimension. Patients were randomised to standard care (chemotherapy 
followed by endocrine therapy) or an Oncotype DX® test (Genomic Health Inc., Redwood City, 
CA, USA) was performed on the surgically resected tumour to assign patients either to standard 
care (if 'recurrence score' (RS) was > 25), or to endocrine therapy alone (if RS was ≤ 25). In this 
feasibility study, ER and HER2 were both reassessed by a central laboratory (UCL Advanced 
Diagnostics) after registration into the trial to confirm eligibility prior to randomisation.  
 
ER was assessed centrally by immunohistochemistry (6F11; Leica Biosystems) and an Allred 
score of 3 or more was regarded as positive, as per national guidance at that time [Harvey JM et 
al. 1999]. If central ER results were discordant with the local report, and there was any doubt, 
the assay was repeated with a second antibody (EP1, Dako). HER2 was re-assessed centrally with 
dual-color dual-hapten brightfield in situ hybridisation (DDISH) (Ventana Medical Systems) and, 
as per UK national guidelines, a ratio of Her2 to chromosome 17 centromeric probe (CEP17) of 
2.00 - 2.20 was considered to represent borderline/positive gene amplification, whilst a ratio of 
Her2:CEP17 of >2.20 was regarded as Her2 gene amplification [Bartlett et al, 2011]. If DDISH 
proved unsuccessful, FISH was attempted using the HER2 PathVysion probe (HER2 PathVysion; 
Abbott Molecular). Her-2 Immunohistochemistry (4B5; Ventana Medical Systems) was applied 
in cases where no result was achievable by either HER2 ISH technique.  
 
Results 
Between October 2012 and August 2014, 442 patients were registered into OPTIMA prelim, but 
11 patients were subsequently withdrawn prior to central testing. Thus a total of 431 patients 
had their tumours tested centrally. Nineteen patients with 21 tumours, showed discrepancies 
in receptor status between local and central laboratories results (4.4%; 95% confidence interval 
(CI) 2.5%-6.3%). The remaining 412 patients (95.6%) with concordant results went on to be 
randomised into OPTIMA prelim. 
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Seven tumours in 7 patients (1.6%) were found to be ER negative on central re-testing (Table 1). 
Two of the 7 were heterogeneous, with an uncommon admixture of ER negative and ER positive 
cells identified in the surgically excised tumour. Two appear to represent true errors in local 
laboratory tests; as local laboratory re-testing on the same sample found the tumours to indeed 
be ER negative. For one patient with 2 eligible tumours and 1 ineligible tumour on central 
review, only the core biopsy was examined locally. Two other cases are unexplained regarding 
the reason for the discordance.  
 
In total 15 tumours in 13 patients (3.0%) from the total 431 patients tested centrally were 
discrepant for HER2 results (Table 2). One patient had one tumour that was centrally categorised 
as ER negative and also showed Her2 amplification (ratio of Her2:CEP17 = 3.59). Seven others 
also showed Her2 amplification (ratio of Her2:CEP17 ranged from 2.39-3.92). An additional 
patient had one tumour that was Her2 amplified and one tumour that was borderline amplified 
(ratio of Her2:CEP17 = 2.78 and 2.11, respectively). The remaining four patients had tumours 
showing borderline Her2 gene amplification (ratio between 2.00-2.20); including one patient 
with two tumours both showing borderline amplification. Only three of the 15 tumours 
demonstrated what some consider ‘high-level’ gene amplification (ratio >3.00) [Starczynski 
2012] and none what others have described as ‘high-grade’ amplification (ratio >/=4.00) [Seol 
2012]. 
 
Discussion 
 
Central re-testing of HER2 positive breast cancers has shown high levels of variability in some 
clinical trials; for example, HER2 positivity was only confirmed in 85.8% of 2,535 patients in the 
North Central Cancer Treatment Group N9831 intergroup adjuvant trial [Perez EA et al 2006]. 
Some of these trials, however, pre-date stringent guidelines for HER2 assessment and reporting 
and the reasons for discordance is often not clear. The value of central re-testing of breast 
cancers defined locally as HER2 negative as an eligibility criterion for other, more recent, clinical 
trials has not been well studied. Outwith clinical trials generally lower degrees of discrepancy, 
have been reported [Vani K 2008][Kaufman 2014]; for example, Kaufman et al identified that 
only 4% of 552 patients with metastatic HER2 negative carcinoma (defined locally) in a large 
observational cohort were HER2 positive on central re-testing [Kaufman 2014]. These data are 
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essentially similar to the results in our UK clinical trial where 4.4% of tumours defined locally as 
HER2 negative were HER2 positive on central re-analysis. 
 
These data highlight that approximately 3% of patients could be being excluded from HER2 
directed therapies due to a potentially faulty local result in real-world testing in the UK. However, 
of note, we report here the proportion of cases that are discordant between local and central 
laboratory testing. Although for 2 cases, repeat re-testing of the same samples locally confirmed 
the tumour was ER negative (rather than ER positivity as initially reported), for others it is only 
possible to record that the other results were “discordant”. It is not per se the case that the 
central laboratory is correct and the local laboratory inaccurate.  
Central repeat testing of hormone receptor status from clinical trial samples have reported 
similar, albeit slightly higher, levels of difference between local and central laboratories than we 
have found. Viale et al. [Viale 2007] examined 6291 of 8010 tumours from women in BIG1-98 
and found that central review confirmed 97% of tumours were hormone receptor-positive, 
although this incorporated both ER and progesterone receptor and with different cut-offs than 
applied as routine in the UK (i.e. defined as ER and/or PgR > or =10%). Indeed, the authors note 
that, of 105 carcinomas that were reported locally as ER negative, 73 had >10%, and eight had 
1% - 9% positive cells. This highlights the difficulty of non-standard definitions globally for 
hormone receptor positivity and the need for pathologists, as well as all other members of the 
multidisciplinary team, to be aware of study protocols and definitions.  
 
Notwithstanding that these results compare favourably to the (albeit limited) published data, 
there are a number of possible explanations for discrepant results between local and central 
laboratories. Additional challenges include variation in methodology (for example, 
immunohistochemistry Vs fluorescence in situ hybridisation (FISH) Vs chromogenic in situ 
hybridisation (DDISH) for assessment of HER2 status), as well as differences in the antibody 
clones used, variation in the material assessed (cores Vs surgical excision specimens) and 
pathologist interpretation. It is well recognised that variation between core biopsy specimens 
and surgical excision is uncommon (<2% of cases showing heterogeneity) [Arnedos 2009][Lee 
2012], although this clearly does occur and may potentially explain variations in receptor status 
if different specimens are submitted for central testing than examined locally. Indeed, this 
variation appears to explain at least 3 of the 7 cases with discrepant ER status in this study. 
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These potential discrepancies are all applicable even if the central review is undertaken in ‘real 
time’, i.e. prior to patient randomisation as in OPTIMA prelim. Nevertheless, particular care must 
be taken when analysing historical data on ER status, even in meta-analysis of clinical trials or 
when comparing to present day results; data extracted from local reports may be based on 
entirely different methodologies; Collins et al examined (on TMA) 1851 cases where tissue and 
histology reports were available and highlighted that in 82% of the cases the original assays were 
biochemical. Even where immunohistochemistry was applied both locally and centrally as the 
technique of choice, agreement was only 92% for ER status (310 of 336 specimens) [Collins 2008]. 
Again, the 1.6% difference seen in OPTIMA prelim compares favourably. 
 
Despite all the potential technical and interpretive differences in biomarker analysis, the results 
from OPTIMA prelim indicate good concordance between local laboratories and central re-
testing centre in the UK in classification of invasive breast cancers as ER positive and HER2 
negative. Such re-testing in large randomised clinical trials recruiting thousands of patients is 
very expensive and, in the setting of this group of patients (as opposed to HER2 positive disease, 
for example, where discrepancies may be higher), the value is questionable.  
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Table 1: Details of the 7 patients (from 431 patients registered and tested centrally) with 
discrepant oestrogen receptor results. 
  
Patient 
CENTRAL ER RESULTS   
ER 
Status 
Allred 
score 
% tumour 
cell 
positivity 
Comment 
A Negative 0 0 Two clonality distinct tumours - part 
positive and part negative for ER. 
Original ER on core biopsy. 
B Negative 0 0 ER repeated in local laboratory on core 
biopsy using different antibody/clone 
and negative staining for ER confirmed. 
C Negative 0 0 ER retested locally and confirmed to be 
negative. 
D Negative 0 0   
E Negative 0 0 Heterogenous tumour, at least focally 
ER negative. 
F Negative 0 0   
G Negative 0 0 3 tumours: 2 eligible, 1 ineligible. 
Local ER on core biopsy. 
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Patien
t 
CENTRAL HER2 RESULTS 
HER2 STATUS 
Her2: 
CEP17 
ratio 
Average 
CEP17 copy 
number per 
cell 
Average 
Her2 copy 
number per 
cell 
Comments 
D Amplified 3.59 1.10 3.95 Also ER negative on central 
testing 
H Borderline 
amplified 
2.00 2.78 5.55 
 
I1* Borderline 
amplified 
2.14 1.65 3.53   
I2* Borderline 
amplified 
2.06 1.69 3.47   
J Borderline 
amplified 
2.20 1.43 3.14   
K Amplified 2.70 2.00 5.40   
L Amplified 2.39 1.55 3.70   
M Amplified 2.81 1.35 3.80 Heterogeneous - testing of 
core (locally) and second 
block (centrally) showed 
Her2 non-amplified foci. 
N Amplified 3.23 2.80 9.05   
O1* Amplified 2.78 1.35 3.75   
O2* Borderline 
amplified 
2.11 1.40 2.95   
P Amplified 2.45 1.10 2.70   
Q Amplified 2.64 1.08 2.83   
R Amplified 3.92 1.8
5 
7.25   
S Borderline 
amplified  
2.11 2.03 4.30   
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Table 2: Details of the 15 discrepant tumours (13 patients) for human epidermal growth factor 
receptor homologue 2 (HER2) status. 
 
Amplified: human epidermal growth factor receptor homologue 2 (HER2) to chromosome 17 
centromeric probe (CEP17) ratio >2.20;  
Borderline amplified: HER2 to CEP17 ratio 2.00-2.20;  
*G1 & G2, and N1 & N2, are tumours from the same patient respectively. 
 
